



PFINZER

4D Pharma

Pipeline • Products • Performance • Potential

CONTENTS

Latest Results	2
EXECUTIVE SUMMARY	5
Introduction	5
Current Financial Position	6
Company Performance.....	6
Business Segment Performance	8
Geographic Segment Performance	10
Company Strategy	12
R&D Strategy	12
Mergers, Acquisitions and Divestitures	13
Key Agreements	15
Discontinued Agreements.....	16
Production	16
Employees.....	16
Product Performance Forecast	18
Discontinued Products.....	20
Pipeline Analysis	21
Discontinued R&D Projects.....	21
Conclusions / Outlook.....	23
THERAPEUTIC AREA FOCUS.....	27
R&D PIPELINE	30
CARDIOVASCULAR / METABOLISM	33
Marketed Products	33
Champix	33
Lipitor	35
Norvasc.....	45
Others	51
R&D Projects.....	52
Apixaban	52
CP-945598.....	53
NOX-B11	53
PF-734200	53
Growth Forecast.....	54
CENTRAL NERVOUS SYSTEM	55
Marketed Products	55
Aricept.....	55
Geodon/Zeldox	59
Lyrica	62
Zolofte.....	65
Others	69
R&D Projects.....	70
PD-332334	70
PF-4360365	70
S,S-reboxetine.....	71
TS-032	71
Growth Forecast.....	72
INFECTIOUS AND RESPIRATORY	73
Marketed Products	73
Eraxis.....	73

Selzentry/Celsentri.....	74
Vfend.....	77
Zyvox/Zyvoxa.....	78
Others	80
R&D Projects.....	82
R343	82
Sulopenem	82
TT-033	83
UK-453061	83
Zeven.....	83
Growth Forecast.....	84
UROLOGY.....	85
Marketed Products	85
Detrusitol/Detrol	85
Toviaz.....	87
Viagra/Revatio.....	87
R&D Projects.....	92
PD-299685.....	92
PF-3274167	92
UK-369003.....	92
Growth Forecast.....	93
ARTHRITIS AND PAIN	94
Marketed Products	94
Celebrex/Celebra	94
R&D Projects.....	102
ADL5747	102
ADL5859.....	103
CCR2 Antagonists	103
CP-690550	103
PF-438119.....	103
Growth Forecast.....	104
ONCOLOGY	105
Marketed Products	105
Sutent.....	105
Others	109
R&D Projects.....	110
Axitinib	111
CDX-110.....	112
CovX 045	113
CovX 060	113
CP-547632.....	114
CP-751871	114
PD-325901	115
PD-332991	115
PF-3512676	115
Growth Forecast.....	116
OPHTHALMOLOGY.....	117
Marketed Products	117
Xalatan/Xalcom/Xalacom	117
Others	119
R&D Projects.....	121

PF-03187207	121	Rigel Pharmaceuticals Inc	162
T2-TrpRS	121	Silence Therapeutics	163
Growth Forecast.....	122	Tacere Therapeutics	163
ENDOCRINE DISORDERS.....	123	Taisho Pharmaceutical.....	163
Marketed Products	123	TransTech Pharma.....	164
Genotropin	123	UCB.....	164
Growth Forecast.....	128	Others	165
WOMEN'S HEALTHCARE	129	APPENDIX 4 - INFRASTRUCTURE.....	166
Marketed Products	129	Manufacturing Facilities.....	166
R&D Projects.....	129	R&D Facilities.....	170
CP-533536.....	129	APPENDIX 5 - KEY PHARMACEUTICAL	
Fablyn.....	129	SUBSIDIARIES/JOINT VENTURES.....	171
Growth Forecast.....	131	Subsidiaries	171
OTHER.....	132	Joint-venture Companies	173
Marketed Products	132	APPENDIX 6 - PRODUCT INDEX	175
Zyrtec/Reactine	132		
R&D Projects.....	135		
PF-04548043	135		
APPENDIX 1 - FINANCIAL PERFORMANCE	139		
Full Year Results 2007	139		
APPENDIX 2 - KEY CORPORATE EVENTS	142		
APPENDIX 3 - KEY AGREEMENTS.....	145		
Adolor Corporation	146		
Allergan	146		
Astellas Pharma Inc	147		
AVANT Immunotherapeutics.....	148		
Bayer Schering Pharma.....	148		
Boehringer Ingelheim	148		
Bristol-Myers Squibb.....	149		
Coley Pharmaceutical Group Inc.....	150		
Eisai	150		
Elusys Therapeutics.....	151		
Five Prime Therapeutics Inc	151		
Genentech Inc	151		
Hydra Biosciences Inc	152		
Icagen Inc.....	152		
Immunicon Corporation.....	153		
Incyte Corporation.....	153		
International Partnership for Microbicides	154		
Isis Pharmaceuticals Inc.....	154		
Ligand Pharmaceuticals Inc.....	155		
Kosan Biosciences	156		
Medarex Inc	156		
Merck KGaA.....	157		
NicOx SA.....	157		
NovaMed Pharmaceuticals Inc.....	159		
Noxxon Pharma AG.....	159		
Onyx Pharmaceuticals Inc.....	159		
OSI Pharmaceuticals Inc/New York University.....	160		
Recordati	161		
Renovis Inc.....	161		

INDEX OF TABLES

<i>Principal Operating Results</i>	1
<i>Capital Expenditure By Business Area</i>	7
<i>Sales By Business Area</i>	8
<i>Operating Income By Business Area</i>	9
<i>Identifiable Assets By Business Area</i>	10
<i>Sales By Destination</i>	10
<i>Long-Lived Assets By Geographical Area</i>	11
<i>Key Patent Expiry Dates</i>	18
<i>Recent Product Approvals</i>	20
<i>Sales By Therapeutic Area/Major Products</i>	27
<i>Breakdown Of Cardiovascular/Metabolic Product Sales</i>	33
<i>Major Cardiovascular/Metabolism Products, 2007</i>	33
<i>Breakdown of CNS Sales</i>	55
<i>Major CNS Products, 2007</i>	55
<i>Breakdown of Infectious Disease/ Respiratory Sales</i>	73
<i>Major Infectious & Respiratory Products, 2007</i>	73
<i>Breakdown of Urology Sales</i>	85
<i>Major Urology Products, 2007</i>	85
<i>Breakdown of Arthritis/Pain Sales</i>	94
<i>Major Arthritis and Pain Products, 2006</i>	94
<i>Breakdown of Oncology Sales</i>	105
<i>Major Oncology Products, 2007</i>	105
<i>Breakdown of Ophthalmology Sales</i>	117
<i>Major Ophthalmology Products, 2007</i>	117
<i>Breakdown of Endocrine Sales</i>	123
<i>Major Endocrine Disorder Products, 2007</i>	123
<i>Breakdown of Other Product Sales</i>	132
<i>Major Other Products, 2007</i>	132
<i>Pfizer's Major Manufacturing Sites</i>	167

INDEX OF CHARTS

<i>Sales, Costs and Operating Income</i>	6
<i>R&D Expenditure & Capital Expenditure</i>	7
<i>Capital Expenditure By Business Area</i>	7
<i>Sales By Business Area</i>	8
<i>Operating Income By Business Area</i>	9
<i>Sales By Destination</i>	11
<i>Employees and Productivity</i>	17
<i>Sales of Current Top Ten Products (2002A-2012E)</i>	19
<i>Sales By Therapeutic Area</i>	28
<i>Top Selling Products, 2007</i>	29
<i>Champix Sales (2002A-2012E)</i>	34
<i>Lipitor Sales (2002A-2012E)</i>	42
<i>Norvasc Sales (2002A-2012E)</i>	50
<i>Apixaban Sales (2010E-2014E)</i>	53
<i>Aricept Sales (2002A-2012E)</i>	58
<i>Geodon/Zeldox Sales (2002A-2012E)</i>	62
<i>Lyrica Sales (2002A-2012E)</i>	64
<i>Zoloft Sales (2002A-2012E)</i>	68
<i>Selzentry/Celsentri Sales (2008E-2012E)</i>	76
<i>Vfend Sales (2002A-2012E)</i>	78
<i>Zyvox Sales (2002A-2012E)</i>	80
<i>Detrol/Detrol LA Sales (2002A-2012E)</i>	87
<i>Viagra Sales (2002A-2012E)</i>	91
<i>Celebrex Sales (2002A-2012E)</i>	100
<i>Sutent Sales (2002A-2012E)</i>	107
<i>Sales Forecast (2009E-2013E)</i>	111
<i>Xalatan/Xalcom Sales (2002A-2012E)</i>	119
<i>Genotropin Sales (2002A-2012E)</i>	127
<i>Fablyn Sales (2008E-2012E)</i>	130
<i>Sales, Costs and Operating Income</i>	140
<i>Profitability and Research Ratios</i>	140
<i>R&D Expenditure and Capital Expenditure</i>	140
<i>Current Assets, Liabilities and Ratio</i>	141
<i>Assets, Cash and Liquidity</i>	141
<i>Employees and Productivity</i>	141